Stew Kroll

Angiotensin II for the Treatment of Vasodilatory Shock

Ashish K. Khanna, Shane English, Xueyuan S. Wang et al. · New England Journal of Medicine · 2017 · 879 citations · Full text

Pharmacy, Pharmacotherapy, Cardiovascular Pharmacotherapy +14

Pivotal Study of Iodine I 131 Tositumomab for Chemotherapy-Refractory Low-Grade or Transformed Low-Grade B-Cell Non-Hodgkin’s Lymphomas

Mark Kaminski, Andrew D. Zelenetz, Oliver W. Press et al. · Journal of Clinical Oncology · 2001 · 586 citations

Medicine, Oncology, Pharmacology +15

Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial

William D. Tap, Zsuzsanna Pápai, Brian A. Van Tine et al. · The Lancet Oncology · 2017 · 306 citations · Full text

Medicine, Oncology, Pharmacology +12

Outcomes in Patients with Vasodilatory Shock and Renal Replacement Therapy Treated with Intravenous Angiotensin II

James A. Tumlin, Raghavan Murugan, Adam M. Deane et al. · Critical Care Medicine · 2018 · 293 citations · Full text

Medicine, Nephrology, Pharmacotherapy +15

Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer

Mitesh J. Borad, Shantan Reddy, Nathan Bahary et al. · Journal of Clinical Oncology · 2014 · 191 citations · Full text

Pharmacy, Oncology, Pharmacology +17